NDAORALTABLET
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
BACTRIM DS (sulfamethoxazole and trimethoprim) by PharmaIN is dihydrofolate reductase inhibitors [moa]. First approved in 1973.
Drug data last refreshed 23h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BACTRIM DS is an oral fixed-dose combination of sulfamethoxazole and trimethoprim, dihydrofolate reductase inhibitors that work synergistically to inhibit bacterial folate metabolism. It is used to treat a broad spectrum of bacterial infections including urinary tract infections, certain pneumonias, and other susceptible infections. The drug has been a foundational antibiotic since 1973 and remains a cost-effective option for many common bacterial conditions.
$0.019BPart D
LOE ApproachingStable
As a legacy product approaching loss of exclusivity with modest Part D volume, the brand team is likely small and focused on cost containment and niche indications rather than aggressive growth.
Mechanism of Action
Dihydrofolate Reductase Inhibitors
Pharmacologic Class:
Dihydrofolate Reductase Inhibitor Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BACTRIM DS offers exposure to mature product management, generic defense strategies, and cost-containment commercialization—valuable skills in an increasingly price-sensitive market. However, the lack of active pipeline activity and approaching LOE means career trajectory is lateral rather than upward; team size is likely minimal and focused on maximizing operational efficiency.
Brand Manager
Worked on BACTRIM DS at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.